Illumina, Inc. (NASDAQ: ILMN) today announced that it has filed another
patent infringement suit against one of BGI Group’s subsidiaries, BGI
Europe A/S. Illumina filed suit in the Maritime & Commercial High Court
“As we have previously stated, Illumina will continue to vigorously
protect our patented technology and file patent suits where appropriate
when our patents are infringed,” said Charles Dadswell, Senior Vice
President and General Counsel for Illumina.
The complaint alleges that BGI’s sequencing products, including the
BGISeq-500, MGISeq-2000, and related chemistry reagents, infringe EP 3
002 289 B1. This patent covers Illumina’s proprietary
sequencing-by-synthesis chemistry. The complaint also alleges that BGI’s
use of the MGISEQ mark infringes Illumina’s registered EU Trademark No.
8972127 for the MISEQ name.
Earlier this year, Illumina filed a patent infringement suit against BGI
Group’s subsidiary, Latvia MGI Tech SIA, in the Düsseldorf Regional
Court in Germany. That complaint alleges that BGI’s sequencing products,
including the BGISeq-500, MGISeq-2000, and related chemistry reagents,
infringe EP 1 530 578 B1.
Illumina is improving human health by unlocking the power of the genome.
Our focus on innovation has established us as the global leader in DNA
sequencing and array-based technologies, serving customers in the
research, clinical, and applied markets. Our products are used for
applications in the life sciences, oncology, reproductive health,
agriculture, and other emerging segments. To learn more, visit www.illumina.com and